Mair Therapeutics Partners with Radboud University on Groundbreaking Research
Mair Therapeutics, a pioneering Dutch biotechnology company specialized in developing therapies focused on neurodegenerative diseases, has initiated a significant scientific collaboration with Radboud University. This partnership aims to expedite the discovery of small-molecule agonists for TMEM175, an important lysosomal ion channel associated with Parkinson's disease.
The Significance of TMEM175
TMEM175 is crucial for maintaining lysosomal homeostasis, a process vital for clearing out misfolded proteins, including alpha-synuclein, which is notoriously linked with Parkinson's disease. Genetic investigations have shown that dysfunction in TMEM175 can heighten the risk of developing Parkinson's, whereas certain protective variants appear to reduce this risk. Mair Therapeutics is focused on leveraging its drug discovery platform to identify small molecules that can boost TMEM175 activity, ultimately aimed at restoring functional lysosomal dynamics.
Research Collaboration Details
Within this exciting collaborative framework, the laboratory led by Dr. Marijn Kuijpers at Radboud University's Donders Centre for Neuroscience will evaluate a range of TMEM175-targeting compounds developed by Mair Therapeutics. The evaluation will take place using human neuron models derived from both Parkinson's disease patients and healthy individuals. Specific assays will focus on lysosomal pH regulation and degradation capacity—two essential functions that are often disrupted in Parkinson's disease.
Expert Insight from Mair's CEO
Dr. Vasily Kazey, CEO of Mair Therapeutics, commented on the collaboration saying, "Parkinson's disease represents one of the most pressing medical challenges we face today. Addressing lysosomal dysfunction presents a compelling opportunity for advancement in treatment." He expressed enthusiasm about the collaboration with Radboud University, noting their distinguished expertise in neuronal biology and Parkinson's research, which will be vital for validating Mair's therapeutic strategy.
Commitment to Neuroscience Innovation
This collaboration underlines Mair Therapeutics' dedication to fostering partnerships within the vibrant neuroscience innovation ecosystem in the East Netherlands. The company recently launched with the backing of investors Torrey Pines Investment and Oost NL, and it is positioned in Nijmegen—a prominent center for Parkinson's disease research, home to the Parkinson expertise center directed by Prof. Dr. Bas Bloem at Radboudumc.
About Mair Therapeutics
Mair Therapeutics is committed to creating first-in-class small-molecule therapeutics that specifically target lysosomal ion channels for treating neurodegenerative diseases. The company’s lead program emphasizes TMEM175 agonists, particularly aimed at addressing Parkinson's disease. The company is headquartered in Nijmegen and is benefitting from substantial support from Torrey Pines Investment, Oost NL, and Expert Systems, reflecting its strong backing in the biotech sphere.
About Radboud University
Radboud University stands out as a premier academic institution in the Netherlands, recognized globally for its contributions to life sciences and neuroscience. The Kuijpers Lab at the Donders Institute focuses on exploring organelle dynamics and intracellular trafficking within neurons, especially in relation to lysosomal biology and models of neurodegenerative diseases.
Frequently Asked Questions
What is the focus of Mair Therapeutics' collaboration with Radboud University?
The collaboration aims to accelerate the discovery of small-molecule agonists for TMEM175, targeting its role in Parkinson's disease.
Why is TMEM175 important in relation to Parkinson's disease?
TMEM175 is essential for lysosomal homeostasis and the clearance of misfolded proteins, with its dysfunction linked to increased risk of developing Parkinson's disease.
Who is leading the research at Radboud University?
The research is led by Dr. Marijn Kuijpers at the Donders Centre for Neuroscience.
What role does Mair Therapeutics' drug discovery platform play?
Mair's platform aims to identify small molecules that enhance TMEM175 activity to restore lysosomal function.
Where is Mair Therapeutics headquartered?
Mair Therapeutics is based in Nijmegen, a key hub for Parkinson's research in the Netherlands.
